Introduction. The present study evaluated the effects of benazepril, an angiotensin-converting enzyme inhibitor on haemodynamic, biochemical, and immunohistochemical (Bax and Bcl-2 protein) indices in ischaemia and reperfusion (IR) injury.
Materials and methods. Male Wistar albino rats were divided into three groups and were orally administered saline once daily (IR-sham and IR-control) or benazepril (30 mg/kg/day; IR-benazepril) for 14 days. On the 15th day, in the IR-control and IR-benazepril groups, rats were subjected to left anterior descending coronary artery occlusion for 45 minutes followed by a one-hour reperfusion. Haemodynamic parameters were recorded and rats were sacrificed; hearts were isolated for biochemical estimation and immunohistochemistry.
Results. In the IR-control group, significant ventricular dysfunctions (p<0.05 vs. IR-sham group) were observed along with enhanced expression of pro-apoptotic protein Bax. A decline in lactate dehydrogenase activity and increased content of thiobarbituric acid reactive substances, a marker of lipid peroxidation, were observed. Benazepril pretreatment significantly improved mean arterial pressure (p<0.01), reduced left ventricular end-diastolic pressure (p<0.05), and improved both inotropic and lusitropic function of the heart (+LVdP/dt and — LVdP/dt) (p<0.05; p<0.01) as compared to IR-control. Furthermore, benazepril treatment significantly decreased the level of thiobarbituric acid reactive substances and restored the activity of lactate dehydrogenase towards normal value (p<0.05 vs. IR-control).
Conclusion. This study demonstrates that benazepril upregulated Bcl-2 protein and decreased Bax protein expression, thus exhibiting anti-apoptotic effects. These beneficial effects of benazepril will have an important implication in the therapeutic use of benazepril in ischaemic heart disease.
Mohanty IR, Arya DS, Gupta SKWithania somnifera provides cardioprotection and attenuates ischemia-reperfusion induced apoptosis. Clin Nutr2008;27:635-42.
2.
Braunwald E. , Kloner RAMyocardial reperfusion: a double-edged sword?J Clin Invest1985;76:1713-19.
3.
Kroemer G., Dallaporta B., Resche-Rigon M.The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol1998;60:619-42.
4.
Buttke TM, Sandstrom PAOxidative stress as a mediator of apoptosis. Immunol Today1994;15(1):7-10.
5.
Gottlieb RA, Burleson KO, Kloner RA et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest1994;94:1621-8.
6.
Olivetti G., Abbi R., Quaini F. et al. Apoptosis in the failing human heart. N Engl J Med1997;336:1131-41.
7.
Veinot JP, Gattinger DA, Fliss H.Early apoptosis in human myocardial infarcts. Hum Pathol1997;28:485-92.
8.
Haunstetter A., Izumo S.Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res1998;82:1111-29.
9.
Maulik N., Yoshida T., Engelman RM et al. Ischemic preconditioning attenuates apoptotic cell death associated with ischemia/reperfusion. Mol Cell Biochem1998;186:139-45.
10.
Haunstetter A., Izumo S.Future perspectives and potential implications of cardiac myocyte apoptosis. Cardiovasc Res2000;45:795-801.
11.
Galang N., Sasaki H., Maulik N.Apoptotic cell death during ischemia/reperfusion and its attenuation by antioxidant therapy. Toxicology2000;148:111-18.
12.
Kobara M., Tatsumi T., Kambayashi D. et al. Effects of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model. J Cardiovasc Pharmacol2003 ;41:880-9.
13.
Pfeffer MA, Braunwald E., Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med1992;327:669-77.
14.
Ertl G., Kloner RA, Alexander RW et al. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation1982;65(1):40-8.
15.
Martorana PA , Kettenbach B., Breipohl G. et al. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist . Eur J Pharmacol1990;182:395-6.
16.
Ozer MK, Sahna E., Birincioglu M. et al. Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. Pharmacol Res2002;45: 257-63.
17.
Liu YH, Yang XP, Sharov VG et al. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension1996;27(1):7-13.
18.
He H., Shi M., Yang X. et al. Comparison of cardioprotective effects using salvianolic acid B and benazepril for the treatment of chronic myocardial infarction in rats . Naunyn Schmiedebergs Arch Pharmacol2008 ;378:311-22.
19.
Singh VP, Le B., Khode R. et al. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes2008;57:3297-306.
20.
Mohanty I., Gupta SK, Arya DSAnti-apoptotic and cardioprotective effects of an herbal combination in rats with experimental myocardial infarction. Int J Integr Biol2007;1:178-88.
21.
Okhawa H., Oohishi N., Yagi N.Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction . Ann Biochem1979;95:351-8.
22.
Cabaud P., Wroblewski F.Colorimetric measurement of lactic dehydrogenase activity of body fluid. Am J Clin Pathol1958;30:234-6.
23.
Misao J., Hayakawa Y., Ohno M. et al. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation1996;94:1506-12.
Opie LHReperfusion injury and its pharmacologic modification. Circulation1989;80:1049-62.
26.
Arya DS, Bansal P., Ojha SK et al. Pyruvate provides cardioprotection in the experimental model of myocardial ischemic reperfusion injury. Life Sci2006;79:38-44.
27.
He HB, Yang XZ, Shi MQ et al. Comparison of cardioprotective effects of salvianolic acid B and benazepril on large myocardial infarction in rats. Pharmacol Rep2008; 60:369-81.
28.
Chen X., Minatoguchi S., Wang N. et al. Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits. J Cardiovasc Pharmacol2003;41:938-45.
29.
Veeravalli KK, Akula A., Kota MKNitric oxide- and prostaglandin-mediated cardioprotection by bradykinin in myocardial ischemia and reperfusion injury . Pol J Pharmacol2003;55:1021-9.
30.
Hartman JCThe role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg1995;60:789-92.
31.
Hornig B., Kohler C., Drexler H.Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation1997 ;95:1115-18.
32.
Koh KK, Bui MN, Hathaway L. et al. Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol1999;83:327-31.
33.
Matoba S., Tatsumi T., Keira N. et al. Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes. Circulation1999;99:817-22.
34.
Yoshida H., Zhang JJ, Chao L. et al. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension2001;35:25-31.
35.
Marktanner R., Nacke P., Feindt P. et al. Delayed preconditioning via angiotensin-converting enzyme inhibition: pros and cons from an experimental study. Clin Exp Pharmacol Physiol2006;33:787-92.
36.
Dormandy TLFree-radical oxidation and antioxidants. Lancet1978;1:647-50.
37.
Ferrari R., Agnoletti L., Comini L. et al. Oxidative stress during myocardial ischaemia and heart failure . Eur Heart J1998;19(suppl B):B2-11.
38.
Sevanian A. , Hochstein P.Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr1985;5:365-90.
39.
Jennings RB , Murry CE, Steenbergen CJR et al. Acute myocardial ischemia: development of cell injury in sustained ischemia. Circulation1990;82:3-12.
40.
Marczin N., El-Habashi N., Hoare GS et al. Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem Biophys2003;420: 222-36.
41.
Bernier M., Hearse DJ, Manning ASReperfusion-induced arrhythmias and oxygen derived free radicals. Circ Res1986; 58:331-40.
42.
Bassenge E. , Sommer O., Schwemmer M. et al. Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state. Am J Physiol Heart Circ Physiol2000;279:H2431-8.
43.
Fliss H., Gattinger D.Apoptosis in ischemic and reperfused rat myocardium. Circ Res1996;79:949-56.
44.
MacLellan WR , Schneider MDDeath by design. Programmed cell death in cardiovascular biology and disease. Circ Res1997;81:137-44.
45.
Narula J., Pandey P., Arbustini E. et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A1999;96:8144-9.
46.
Cesselli D. , Jakoniuk I., Barlucchi L. et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res2001 ;89:279-86.
47.
Chao DT, Korsmeyer SJBcl-2 family: regulators of cell death. Annu Rev Immunol1998;16:395-419.
48.
Cook SA, Sugden PH, Clerk A.Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. Circ Res1999;85:940-9.
49.
Danial NN, Korsmeyer SJCell death: critical control points. Cell2004;116:205-19.
50.
Gustafsson AB, Gottlieb RABcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol2007; 292:C45-51.
